[{"orgOrder":0,"company":"Fosun Wanbang Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"||DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fosun Wanbang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Fosun Wanbang Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Wanbang Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"||DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"||DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leflunomide","moa":"||DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"||BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | ","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leflunomide","moa":"||Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | ","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | "}]

Find Clinical Drug Pipeline Developments & Deals for CAS-75706-12-6

CAS-75706-12-6
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

CAS-75706-12-6

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

24 API Suppliers, 6 USDMF, 4 CEP/COS, 4 EU WC, 3 KDMF, 7 NDC API, 18 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

240 FDF Dossiers, 27 FDA Orange Book, 92 Europe, 20 Canada, 60 Australia, 10 South Africa, 31 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 100MG, TABLET;ORAL - 10MG, TABLET;ORAL - 20MG

RELATED EXCIPIENT COMPANIES

3 SPI Pharma, 5 DKSH, 5 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 5 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 23 BASF, 10 Corel Pharma Chem, 4 DFE Pharma, 1 Esteem Industries, 1 Finar, 11 Gangwal Chemicals, 3 Ideal Cures, 3 Ingredion Pharma Solutions, 23 Kerry, 1 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 1 Nanjing Bold Chemical, 1 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 9 Roquette, 13 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 4 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Fillers, Diluents & Binders, 39 Coating Systems & Additives, 28 Disintegrants & Superdisintegrants, 28 Direct Compression, 25 Granulation, 23 Solubilizers, 19 Controlled & Modified Release, 15 Thickeners and Stabilizers, 12 Lubricants & Glidants, 11 Topical, 9 Chewable & Orodispersible Aids, 9 Film Formers & Plasticizers, 8 Parenteral, 7 Emulsifying Agents, 6 Co-Processed Excipients, 6 Taste Masking, 5 Empty Capsules, 5 API Stability Enhancers, 5 Rheology Modifiers, 4 Vegetarian Capsules, 4 Coloring Agents, 2 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 7 News #PharmaBuzz

GLOBAL SALES INFORMATION

10 US Medicaid Prescriptions, 75 Regulatory FDF Prices

MARKET PLACE

20 APIs, 2 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM, 6 USP, 3 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Azathioprine,Chloroquine Phosphate,Hydroxychloroquine Sulphate,Leflunomide,Methotrexate,Sulfasalazine

Therapeutic Area : Immunology

Study Phase : Phase IV

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

February 28, 2018

Lead Product(s) : Sarilumab,Azathioprine,Chloroquine Phosphate,Hydroxychloroquine Sulphate,Leflunomide,Methotrexate,Sulfasalazine

Therapeutic Area : Immunology

Highest Development Status : Phase IV

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Sulfasalazine,Leflunomide,Bucillamine,Tacrolimus,Mizoribine

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese P...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

February 26, 2015

Lead Product(s) : Sarilumab,Sulfasalazine,Leflunomide,Bucillamine,Tacrolimus,Mizoribine

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Methotrexate,Sulfasalazine,Leflunomide,Hydroxychloroquine Sulphate

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

February 07, 2014

Lead Product(s) : Sarilumab,Methotrexate,Sulfasalazine,Leflunomide,Hydroxychloroquine Sulphate

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Hydroxychloroquine Sulphate,Methotrexate,Sulfasalazine,Leflunomide

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who A...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

January 15, 2013

Lead Product(s) : Sarilumab,Hydroxychloroquine Sulphate,Methotrexate,Sulfasalazine,Leflunomide

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

05

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sarilumab,Hydroxychloroquine Sulphate,Methotrexate,Sulfasalazine,Leflunomide

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Respondin...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

October 18, 2012

Lead Product(s) : Sarilumab,Hydroxychloroquine Sulphate,Methotrexate,Sulfasalazine,Leflunomide

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

06

RemeGen

China

EPSC

Not Confirmed

07

Aurobindo Pharma Limited

India

EPSC

Not Confirmed

08

Chinese SLE Treatment And Research Group

Country

EPSC

Not Confirmed

09

Lupin Ltd

India

EPSC

Not Confirmed

10

Fosun Wanbang Pharmaceutical

China

EPSC

Not Confirmed

1
2